Lotus Pharmaceuticals, Inc. (LTUS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 72.69 Million |
| Cost of Revenue | - | - | - | - | - | 32.91 Million |
| Gross Profit | - | - | - | - | - | 39.78 Million |
| Operating Expenses | 18.81 Thousand | 21.1 Thousand | 30.41 Thousand | 6283.00 | -21.82 Thousand | 18.49 Million |
| Selling, General and Administrative Expenses | 18.81 Thousand | 21.1 Thousand | 30.41 Thousand | 6283.00 | - | 18.4 Million |
| Research and Development Expenses | - | - | - | - | - | 86.54 Thousand |
| Other Expenses | - | - | - | - | -21.82 Thousand | -3.44 Million |
| Cost and Expenses | 18.81 Thousand | 21.1 Thousand | 30.41 Thousand | 6283.00 | -21.82 Thousand | 51.41 Million |
| Operating Income | -18.81 Thousand | -21.11 Thousand | -30.41 Thousand | -6280.00 | -21.82 Thousand | 14.52 Million |
| Interest Expense | - | - | - | - | - | 612.62 Thousand |
| Income Tax Expense | -167.89 Thousand | -228.48 Thousand | -236.55 Thousand | -206.29 Thousand | 21.82 Thousand | 220.29 Thousand |
| Earnings before Tax | -18.81 Thousand | -21.1 Thousand | -30.41 Thousand | -6283.00 | - | 14.64 Million |
| Net Income | -18.81 Thousand | -21.1 Thousand | -30.41 Thousand | -6283.00 | -21.82 Thousand | 14.42 Million |
| Earnings Per Share Basic | - | - | - | - | - | 0.28 |
| Earnings Per Share Diluted | - | - | - | - | - | 0.27 |
| Weighted Average Shares Outstanding | 2.69 Billion | 2.69 Billion | 2.94 Billion | 2.94 Billion | 2.79 Billion | 52.35 Million |
| Weighted Average Shares Outstanding (Diluted) | 2.69 Billion | 2.69 Billion | 2.94 Billion | 2.94 Billion | 2.79 Billion | 53.99 Million |
| Gross Margin | - | - | - | - | - | 0.55 |
| EBIT Margin | - | - | - | - | - | 0.32 |
| Profit Margin | - | - | - | - | - | 0.20 |
| EBITDA | -18.81 Thousand | -21.11 Thousand | -30.41 Thousand | -6280.00 | -21.82 Thousand | 17.55 Million |
| Earnings Before Tax Margin | - | - | - | - | - | 0.20 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 2500.00 | 5732.00 | 18.81 Thousand | 3622.00 | 4425.00 | 4150.00 |
| Selling, General and Administrative Expenses | 2500.00 | 5732.00 | - | 3622.00 | 4425.00 | 4150.00 |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 2500.00 | 5732.00 | 18.81 Thousand | 3622.00 | 4425.00 | 4150.00 |
| Operating Income | -2500.00 | -5730.00 | -18.81 Thousand | -3620.00 | -4425.00 | -4150.00 |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | -43.27 Thousand | -167.89 Thousand | -43.81 Thousand | 39.58 Thousand | -122.08 Thousand |
| Earnings before Tax | -2500.00 | -5732.00 | -18.81 Thousand | -3622.00 | -4425.00 | -4150.00 |
| Net Income | -2500.00 | -5732.00 | -18.81 Thousand | -3622.00 | -4425.00 | -4150.00 |
| Earnings Per Share Basic | - | - | - | - | - | - |
| Earnings Per Share Diluted | - | - | - | - | - | - |
| Weighted Average Shares Outstanding | 2.69 Billion | 2.69 Billion | 2.69 Billion | 2.69 Billion | 2.69 Billion | 2.69 Billion |
| Weighted Average Shares Outstanding (Diluted) | 2.69 Billion | 2.69 Billion | 2.69 Billion | 2.69 Billion | 2.69 Billion | 2.69 Billion |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -2500.00 | -5730.00 | - | -3620.00 | -4425.00 | -4150.00 |
| Earnings Before Tax Margin | - | - | - | - | - | - |
SRAX
600667
TTI
CAT-A
TNISF
ILYDA